Summary
0QF Chart
Moderna, favored by the first Trump administration for its Covid-19 vaccine, is now in trouble as Trump 2.0 shifts its position on vaccine-making
The biotech's mRNA vaccines were lauded by the first Trump administration but now are caught up in government changes to vaccine rules.
Moderna: Vaccine Approval (Finally!) Provides A Reason To Be Cheerful
Moderna's new COVID vaccine approval targets a broader high-risk population, but the market remains skeptical due to limited revenue prospects and ongoing losses. Management is pivoting to cost-cutting, pipeline focus, and realistic revenue guidance after overreaching post-pandemic and burning through cash on speculative projects. Despite leadership changes at HHS and FDA and loss of government funding, Moderna could outperform 2025 guidance if vaccination rates and combo shots gain traction.
Moderna moves higher on FDA approval of new COVID-19 vaccine
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares edged higher after the US Food and Drug Administration (FDA) approved its newest COVID-19 vaccine mNEXSPIKE (mRNA-1283). The vaccine was approved for use in adults aged 65 and older and individuals aged 12 to 64 who have at least one underlying health risk factor as defined by the Centers for Disease Control and Prevention (CDC), Moderna said on Monday.
Moderna Inc. Dividends
Moderna Inc. Earnings
| 30 Jul 2025 (57 Days) Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 20 Feb 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 30 Jul 2025 (57 Days) Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 20 Feb 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
Moderna Inc. (0QF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Moderna Inc. ever had a stock split?
Moderna Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Stephane Bancel CEO | XSTU Exchange | US60770K1079 ISIN |
| US Country | 5,800 Employees | - Last Dividend | - Last Split | 7 Dec 2018 IPO Date |
Overview
Moderna, Inc., is a pioneering biotechnology firm founded in 2010, with its headquarters located in Cambridge, Massachusetts. Initially known as Moderna Therapeutics, Inc., the company rebranded to Moderna, Inc. in August 2018. It specializes in leveraging messenger RNA (mRNA) technology to develop, discover, and commercialize therapeutics and vaccines for a wide array of diseases. These diseases range from infectious diseases, immuno-oncology, rare diseases, to autoimmune and cardiovascular diseases. Moderna's operations span across the United States, Europe, and globally. The company has established strategic alliances and collaborations with notable entities in the biotech and pharmaceutical industry, including AstraZeneca, Merck & Co., Inc, Vertex Pharmaceuticals, Chiesi Farmaceutici S.p.A., and The Bill & Melinda Gates Foundation, among others.
Products and Services
- Respiratory Vaccines
Moderna's respiratory portfolio includes vaccines against COVID-19, influenza, and respiratory syncytial virus. The company utilizes its mRNA technology to develop vaccines like Spikevax, as well as its hMPV/PIV3 vaccine candidates, targeting multiple respiratory pathogens.
- Latent Vaccines
The latent vaccines developed by Moderna target a variety of viruses such as the cytomegalovirus, Epstein-Barr virus, herpes simplex virus, varicella zoster virus, and the human immunodeficiency virus. These vaccines aim to provide immunity against viruses that remain dormant in the body and can cause disease upon reactivation.
- Public Health Vaccines
Moderna's public health vaccines include projects against diseases like Zika, Nipah, and Mpox. These vaccines are part of Moderna's commitment to addressing emerging public health threats and pandemics with swift vaccine development.
- Infectious Diseases Vaccines
Vaccines against Lyme disease and norovirus fall under this category. Moderna leverages its mRNA platform to create vaccines designed to protect against widespread and challenging infectious diseases.
- Systemic Secreted and Cell Surface Therapeutics
This innovative category includes therapies that are administered systemically to target secreted and cell surface proteins, leveraging mRNA technology for treating various conditions beyond infectious diseases, including potential treatments for autoimmune and cardiovascular diseases.
- Cancer Vaccines
Moderna's oncology portfolio includes personalized cancer vaccines, KRAS vaccines, and checkpoint vaccines. These products represent an extension of mRNA technology into the field of immuno-oncology, targeting the immune system to fight cancer.
- Intratumoral Immuno-Oncology Products
These are innovative treatments administered directly into tumors to elicit a more potent and localized immune response against cancer. They form part of Moderna's broader strategy to harness the body's immune system in combating cancer.
- Rare Disease Intracellular Therapeutics
Moderna is developing therapies for rare diseases by targeting intracellular mechanisms. These therapeutics are designed to address genetic disorders and diseases with limited treatment options.
- Inhaled Pulmonary Therapeutics
The company is also exploring the potential of inhaled therapies for diseases affecting the lungs, utilizing its mRNA technology to create novel treatments for pulmonary conditions.
Contact Information
